News

The Evolution of Lenacapavir in HIV Treatment

Published: | Updated:

The antiviral began its development as a multidrug-resistant therapy for people with HIV, and has since been studied as PrEP intervention, with many now calling for it to be made widely available for mass distribution.

A pilot study looked at offering this form of pre-exposure prophylaxis (PrEP) to a select population to see if it could be effective in preventing sexually transmitted infections (STIs).

Despite advances in antiviral treatments, the study reveals that traditional prevention strategies have not curbed reinfection rates among men who have sex with men linked to specific high-risk behaviors.